Citadel Advisors’s Abiomed Inc ABMD Stock Holding History

Citadel Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,300	Closed	-$3.51M	–	15830
2022 Q3	$3.51M	Buy	14,300 +3,200	+29%	+$864K	﹤0.01%	4493
2022 Q2	$2.75M	Sell	11,100 -9,000	-45%	-$2.43M	﹤0.01%	4925
2022 Q1	$6.66M	Sell	20,100 -35,700	-64%	-$11M	﹤0.01%	3630
2021 Q4	$20M	Sell	55,800 -10,900	-16%	-$3.68M	﹤0.01%	2022
2021 Q3	$21.7M	Buy	66,700 +6,700	+11%	+$2.27M	﹤0.01%	1900
2021 Q2	$18.7M	Buy	60,000 +1,200	+2%	+$368K	﹤0.01%	2167
2021 Q1	$18.7M	Sell	58,800 -55,300	-48%	-$17.7M	﹤0.01%	2054
2020 Q4	$37M	Buy	114,100 +16,600	+17%	+$4.59M	0.01%	1211
2020 Q3	$27M	Sell	97,500 -11,100	-10%	-$3.2M	0.01%	1316
2020 Q2	$26.2M	Sell	108,600 -8,800	-7%	-$1.77M	0.01%	1271
2020 Q1	$17M	Sell	117,400 -41,800	-26%	-$6.94M	0.01%	1361
2019 Q4	$27.2M	Buy	159,200 +34,500	+28%	+$6.4M	0.01%	1218
2019 Q3	$22.2M	Sell	124,700 -14,000	-10%	-$3.03M	0.01%	1372
2019 Q2	$36.1M	Sell	138,700 -13,400	-9%	-$3.56M	0.02%	938
2019 Q1	$43.4M	Buy	152,100 +57,700	+61%	+$19.2M	0.02%	771
2018 Q4	$30.7M	Sell	94,400 -67,300	-42%	-$23.4M	0.02%	909
2018 Q3	$72.7M	Buy	161,700 +86,700	+116%	+$34.2M	0.03%	555
2018 Q2	$30.7M	Buy	75,000 +36,000	+92%	+$13M	0.02%	971
2018 Q1	$11.3M	Buy	39,000 +11,300	+41%	+$2.86M	0.01%	1594
2017 Q4	$5.19M	Buy	27,700 +18,500	+201%	+$3.45M	﹤0.01%	2437
2017 Q3	$1.55M	Buy	9,200 +6,200	+207%	+$938K	﹤0.01%	3713
2017 Q2	$430K	Sell	3,000 -4,800	-62%	-$645K	﹤0.01%	5337
2017 Q1	$977K	Buy	7,800 +1,000	+15%	+$116K	﹤0.01%	4032
2016 Q4	$766K	Sell	6,800 -4,400	-39%	-$510K	﹤0.01%	4237
2016 Q3	$1.44M	Buy	11,200 +3,400	+44%	+$407K	﹤0.01%	3375
2016 Q2	$852K	Sell	7,800 -4,400	-36%	-$438K	﹤0.01%	3767
2016 Q1	$1.16M	Sell	12,200 -4,300	-26%	-$363K	﹤0.01%	3305
2015 Q4	$1.49M	Sell	16,500 -9,600	-37%	-$815K	﹤0.01%	3087
2015 Q3	$2.42M	Buy	26,100 +11,100	+74%	+$978K	﹤0.01%	2712
2015 Q2	$986K	Buy	15,000 +3,200	+27%	+$213K	﹤0.01%	3973
2015 Q1	$845K	Buy	11,800 +11,400	+2,850%	+$619K	﹤0.01%	4154
2014 Q4	$15K	Buy	+400	New	+$12.6K	﹤0.01%	7987
2014 Q3	–	Sell	-2,700	Closed	-$68K	–	8511
2014 Q2	$68K	Sell	2,700 -800	-23%	-$18.6K	﹤0.01%	6526
2014 Q1	$91K	Sell	3,500 -2,000	-36%	-$55.3K	﹤0.01%	6286
2013 Q4	$147K	Sell	5,500 -3,800	-41%	-$93.9K	﹤0.01%	5305
2013 Q3	$177K	Buy	9,300 +8,400	+933%	+$192K	﹤0.01%	4876
2013 Q2	$19K	Buy	+900	New	+$18.1K	﹤0.01%	6088

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's ABMD Position: Q4 2022 in Review

Citadel Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,005 shares — an estimated $493K sold.

Citadel Advisors first reported a position in ABMD in Q2 2013 and held it in 33 quarters. The position peaked at $79.6M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

Citadel Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 2,005 Abiomed Inc shares in Q4 2022, an estimated $493K.
Citadel Advisors first reported a position in Abiomed Inc in Q2 2013 and held it in 33 quarters.
Citadel Advisors's Abiomed Inc position peaked at $79.6M in Q3 2018.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.